Phosphorylation bar-coding of Free Fatty Acid receptor 2 is generated in a tissue-specific manner
Abstract Free Fatty Acid receptor 2 (FFA2) is activated by short-chain fatty acids and expressed widely, including in white adipocytes and various immune and enteroendocrine cells. Using both wild type human FFA2 and a Designer Receptor Exclusively Activated by Designer Drugs (DREADD) variant we explored the activation and phosphorylation profile of the receptor, both in heterologous cell lines and in tissues from transgenic knock-in mouse lines expressing either human FFA2 or the FFA2-DREADD. FFA2 phospho-site specific antisera targeting either pSer296/pSer297or pThr306/pThr310provided sensitive biomarkers of both constitutive and agonist-mediated phosphorylation as well as an effective means to visualise agonist-activated receptorsin situ. In white adipose tissue phosphorylation of residues Ser296/Ser297was enhanced upon agonist activation whilst Thr306/Thr310did not become phosphorylated. By contrast, in immune cells from Peyer’s patches Thr306/Thr310become phosphorylated in a strictly agonist-dependent fashion whilst in enteroendocrine cells of the colon both Ser296/Ser297and Thr306/Thr310were poorly phosphorylated. The concept of phosphorylation bar-coding has centred to date on the potential for different agonists to promote distinct receptor phosphorylation patterns. Here we demonstrate that this occurs for the same agonist-receptor pairing in different patho-physiologically relevant target tissues. This may underpin why a single G protein-coupled receptor can generate different functional outcomes in a tissue-specific manner.Significance Statement The concept that agonist-occupancy of a G protein-coupled receptor can result in distinct patterns of phosphorylation of residues on the intracellular elements of the receptor in different tissues is referred to ‘bar-coding’. This has been challenging to demonstrate conclusively in native tissues. We now show this to be the case by using tissues from transgenic knock-in mouse lines expressing either wild type or a DREADD variant of human Free Fatty Acid Receptor 2 and a pair of phospho-site specific antisera. Clear differences in the pattern of phosphorylation of the receptor induced by the same ligand were observed in white adipose tissue and immune cells derived from Peyer’s patches. These outcomes provide direct evidence in tissues, at endogenous expression levels, of a well promoted hypothesis..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
bioRxiv.org - (2024) vom: 23. Apr. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Barki, Natasja [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| doi: |
10.1101/2023.09.01.555873 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI040710750 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI040710750 | ||
| 003 | DE-627 | ||
| 005 | 20240425104613.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230902s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2023.09.01.555873 |2 doi | |
| 035 | |a (DE-627)XBI040710750 | ||
| 035 | |a (biorXiv)10.1101/2023.09.01.555873 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Barki, Natasja |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Phosphorylation bar-coding of Free Fatty Acid receptor 2 is generated in a tissue-specific manner |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Free Fatty Acid receptor 2 (FFA2) is activated by short-chain fatty acids and expressed widely, including in white adipocytes and various immune and enteroendocrine cells. Using both wild type human FFA2 and a Designer Receptor Exclusively Activated by Designer Drugs (DREADD) variant we explored the activation and phosphorylation profile of the receptor, both in heterologous cell lines and in tissues from transgenic knock-in mouse lines expressing either human FFA2 or the FFA2-DREADD. FFA2 phospho-site specific antisera targeting either pSer296/pSer297or pThr306/pThr310provided sensitive biomarkers of both constitutive and agonist-mediated phosphorylation as well as an effective means to visualise agonist-activated receptorsin situ. In white adipose tissue phosphorylation of residues Ser296/Ser297was enhanced upon agonist activation whilst Thr306/Thr310did not become phosphorylated. By contrast, in immune cells from Peyer’s patches Thr306/Thr310become phosphorylated in a strictly agonist-dependent fashion whilst in enteroendocrine cells of the colon both Ser296/Ser297and Thr306/Thr310were poorly phosphorylated. The concept of phosphorylation bar-coding has centred to date on the potential for different agonists to promote distinct receptor phosphorylation patterns. Here we demonstrate that this occurs for the same agonist-receptor pairing in different patho-physiologically relevant target tissues. This may underpin why a single G protein-coupled receptor can generate different functional outcomes in a tissue-specific manner.Significance Statement The concept that agonist-occupancy of a G protein-coupled receptor can result in distinct patterns of phosphorylation of residues on the intracellular elements of the receptor in different tissues is referred to ‘bar-coding’. This has been challenging to demonstrate conclusively in native tissues. We now show this to be the case by using tissues from transgenic knock-in mouse lines expressing either wild type or a DREADD variant of human Free Fatty Acid Receptor 2 and a pair of phospho-site specific antisera. Clear differences in the pattern of phosphorylation of the receptor induced by the same ligand were observed in white adipose tissue and immune cells derived from Peyer’s patches. These outcomes provide direct evidence in tissues, at endogenous expression levels, of a well promoted hypothesis. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Jenkins, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Marsango, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Dedeo, Domonkos |e verfasserin |4 aut | |
| 700 | 1 | |a Bolognini, Daniele |e verfasserin |4 aut | |
| 700 | 1 | |a Dwomoh, Louis |e verfasserin |4 aut | |
| 700 | 1 | |a Abdelmalik, Aisha M. |e verfasserin |4 aut | |
| 700 | 1 | |a Nilsen, Margaret |e verfasserin |4 aut | |
| 700 | 1 | |a Stoffels, Manon |e verfasserin |4 aut | |
| 700 | 1 | |a Nagel, Falko |e verfasserin |4 aut | |
| 700 | 1 | |a Schulz, Stefan |e verfasserin |4 aut | |
| 700 | 1 | |a Tobin, Andrew B. |e verfasserin |4 aut | |
| 700 | 1 | |a Milligan, Graeme |e verfasserin |0 (orcid)0000-0002-6946-3519 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2024) vom: 23. Apr. |
| 773 | 1 | 8 | |g year:2024 |g day:23 |g month:04 |
| 856 | 4 | 0 | |u https://doi.org/10.7554/eLife.91861 |x 0 |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2023.09.01.555873 |x 0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 23 |c 04 | ||